However, growing comprehensive analysis of MYCN-amplified neuroblastomas dovetails with early discoveries of basic cancer research, on both in vitro transformation or in vivo tumorigenesis, and CDK4 and RAS-MEK pathways have reemerged as candidates to stop the cell cycle via MYCN-driven aberrant proliferation (Figure 3A). The gene discussed is MYCN; the disease is cancer.